SPP1 and inflammatory response: Moreover, alirocumab not only affects lipid levels but may also offer additional cardiovascular benefits by reducing the activity of inflammatory cytokines (such as IL-18, IL-6, TNF-α) and other molecules associated with vascular inflammation (such as MMP-2, OPN, OPG) [93–95].